AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
55,000
Employees55,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
55,000
Employees55,000

ABBV Key Statistics

Market cap
389.78B
Market cap389.78B
Price-Earnings ratio
166.06
Price-Earnings ratio166.06
Dividend yield
2.98%
Dividend yield2.98%
Average volume
5.91M
Average volume5.91M
High today
$222.49
High today$222.49
Low today
$218.71
Low today$218.71
Open price
$221.17
Open price$221.17
Volume
835.87K
Volume835.87K
52 Week high
$244.81
52 Week high$244.81
52 Week low
$164.39
52 Week low$164.39

Stock Snapshot

AbbVie(ABBV) stock is priced at $220.54, giving the company a market capitalization of 389.78B. It carries a P/E multiple of 166.06 and pays a dividend yield of 3.0%.

As of 2026-01-12, AbbVie(ABBV) stock has fluctuated between $218.71 and $222.49. The current price stands at $220.54, placing the stock +0.8% above today's low and -0.9% off the high.

The AbbVie(ABBV)'s current trading volume is 835.87K, compared to an average daily volume of 5.91M.

In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.

In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.

ABBV News

TipRanks 3h
RemeGen Signs Up to US$5.6 Billion Global Licensing Deal with AbbVie for Cancer Drug RC148

Claim 70% Off TipRanks Premium An update from RemeGen Co. Ltd. Class H ( (HK:9995) ) is now available. RemeGen Co., Ltd. has signed an exclusive global licens...

TipRanks 3h
AbbVie, RemeGen announce exclusive licensing agreement for RC148

AbbVie (ABBV) and RemeGen announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational...

Nasdaq 4h
West To Sell SmartDose 3.5mL On-Body Delivery System To AbbVie For $112.5 Mln

(RTTNews) - West Pharmaceutical Services, Inc. (WST) on Monday said it has agreed to sell all manufacturing and supply rights for its SmartDose 3.5mL On-Body De...

West To Sell SmartDose 3.5mL On-Body Delivery System To AbbVie For $112.5 Mln

Analyst ratings

65%

of 31 ratings
Buy
64.5%
Hold
32.3%
Sell
3.2%

More ABBV News

TipRanks 5h
AbbVie to acquire Arizona manufacturing facility, IP from West Pharmaceutical

AbbVie (ABBV) and West Pharmaceutical (WST) announced a definitive agreement for AbbVie to acquire a device manufacturing facility in Tempe, Arizona and associa...

TipRanks 3d
STAT’s Adam Feuerstein says Revolution Medicines canceled meeting

STAT’s Adam Feuerstein said viax that, “$RVMD – I had a meeting scheduled with the CEO on Monday morning. The company just cancelled. #JPM26 RevMed is also sche...

TipRanks 3d
AbbVie’s ABBV-243 Phase 1 Trial: What Early Safety Work Means for Long-Term Investors

Abbvie (ABBV) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview AbbVie is running a Phase 1 trial called “A...

Nasdaq 3d
Here's What We Expect From AbbVie's Immunology Segment in Q4

AbbVie ABBV generates a substantial portion of its revenues from its immunology franchise, driven by the encouraging uptake of its two blockbuster drugs — Skyri...

Here's What We Expect From AbbVie's Immunology Segment in Q4
Nasdaq 4d
AbbVie Shares Cross 3% Yield Mark

Looking at the universe of stocks we cover at Dividend Channel , in trading on Friday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 3% mark based...

AbbVie Shares Cross 3% Yield Mark
Benzinga 4d
What's Going With Cancer Biotech Erasca Stock On Thursday?

Erasca Inc. (NASDAQ:ERAS) shares on Wednesday jumped close to 60% to $6.12. On Thursday, the stock fell as low as $4.33. • Erasca shares are advancing steadily...

What's Going With Cancer Biotech Erasca Stock On Thursday?
TipRanks 4d
AbbVie Advances Icalcaprant Trial in Depression: What Investors Should Watch

Abbvie (ABBV) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for...

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.